Financial Performance - The company's revenue for Q3 2025 reached ¥139,312,848.65, an increase of 11.27% compared to the same period last year[4] - Net profit attributable to shareholders was ¥31,668,724.25, representing a significant increase of 339.92% year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥25,240,026.54, showing a remarkable growth of 5,439.21% compared to the previous year[4] - Basic earnings per share for the period was ¥0.26, up 333.33% year-on-year[4] - Total operating revenue increased to ¥487,715,534.85, up 25.9% from ¥387,196,007.94 in the previous period[18] - Operating profit rose significantly to ¥120,178,239.04, compared to ¥45,981,613.25 in the prior period, marking a growth of 161.5%[19] - Net profit for the period reached ¥103,429,320.45, a substantial increase of 63.1% from ¥39,290,561.22 year-over-year[19] - Earnings per share (EPS) improved to ¥0.86, up from ¥0.33, reflecting a growth of 160.6%[19] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,325,697,571.21, reflecting a 2.75% increase from the end of the previous year[4] - The total assets of the company amounted to ¥2,325,697,571.21, compared to ¥2,263,389,145.02, marking an increase of about 2.8%[16] - The company's total liabilities increased to ¥121,449,743.86 from ¥114,569,854.99, which is an increase of approximately 6.5%[16] - Total current assets reached ¥1,674,380,425.62, up from ¥1,503,877,958.89, reflecting a growth of approximately 11.3%[14] - Non-current assets decreased to ¥651,317,145.59 from ¥759,511,186.13, showing a decline of about 14.2%[16] - The company’s total equity remained stable at ¥120,446,669.00[16] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥149,201,647.03, an increase of 13.10%[4] - Cash flow from operating activities generated ¥149,201,647.03, an increase of 13.1% compared to ¥131,914,298.83 in the previous period[21] - The company experienced a net cash inflow from investment activities of ¥125,851,446.54, compared to ¥101,423,525.56 in the previous period, an increase of 24.1%[21] - Cash and cash equivalents increased to ¥415,345,384.91 from ¥191,177,985.31, representing a growth of approximately 117.5%[14] - Cash and cash equivalents at the end of the period totaled ¥415,345,384.91, down from ¥644,881,050.63, a decrease of 35.5%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,088[10] - Kingchem (China) holds 48.66% of the shares, making it the largest shareholder[10] Other Financial Metrics - The company reported a significant increase in receivables, with notes receivable rising by 108.59% to ¥60,144,210.32 due to increased revenue[8] - The company experienced a 941.95% increase in taxes payable, amounting to ¥2,895,967.10, attributed to the growth in revenue scale[8] - Accounts receivable rose to ¥80,233,518.31 from ¥74,601,150.11, indicating an increase of about 7.2%[14] - The company’s inventory decreased to ¥147,484,364.70 from ¥194,971,270.02, representing a decline of approximately 24.3%[14] - The company held short-term borrowings of ¥0, indicating no reliance on short-term debt[16] - The company’s deferred income tax liabilities slightly increased to ¥10,047,928.15 from ¥10,031,070.23, reflecting a marginal increase of about 0.2%[16] - The company reported a decrease in research and development expenses to ¥21,034,142.35 from ¥24,554,055.59, indicating a reduction of 14.3%[18] - Other comprehensive income after tax decreased to -¥3,465,005.78 from -¥1,484,846.41, reflecting a decline of 133.4%[19] Accounting Standards - The third quarter financial report of Jinkai (Liaoning) Life Science Technology Co., Ltd. has not been audited[23] - The new accounting standards will be implemented starting from 2025, affecting the financial statements from the beginning of that year[22]
金凯生科(301509) - 2025 Q3 - 季度财报